Skip to main content
Premium Trial:

Request an Annual Quote

D'Trends's Joint Venture Launches Informatics Tool

Premium

SAN RAMON, Calif.--D'Meditis, a joint venture formed in 1998 between Meditis, a Ukranian medical information technology firm, and bioinformatics company D'Trends, launched a new software tool last month. UMics for Healthcare is an integrated all-purpose tool for tracking medical information in distributed and local environments.

Josh Buessing, marketing director of D'Trends, said, "UMics reaffirms our commitment to providing quality software tools to meet the needs of the healthcare sector." Buessing added, "It is also a concentric extension of our product line in the biotech and pharmaceutical discovery domain. The joint venture is an indication of our very successful strategic partnership position with other complementary organizations."

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.